Related Experiment Video
Updated: Dec 24, 2025

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Current approaches in the treatment of catheter-related deep venous thrombosis in children
Julie Jaffray1,2, Neil Goldenberg3,4,5
1Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital Los Angeles , Los Angeles, CA, USA.
Insights
Central venous catheters (CVCs) in children commonly cause venous thromboembolism (VTE). New direct oral anticoagulants (DOACs) show promise for prevention and treatment, but high-risk children need more study.
Area of Science:
- Pediatric Hematology
- Vascular Access Management
- Thrombosis Research
Background:
- Central venous catheters (CVCs) are essential for acutely ill children but pose a significant risk for venous thromboembolism (VTE).
- CVCs are the leading risk factor for VTE in the pediatric population.
- Limited FDA-approved anticoagulants exist for pediatric VTE treatment and prophylaxis.
Purpose of the Study:
- To review the current understanding of CVC-related VTE in children.
- To discuss the epidemiology, risk factors, and management strategies for pediatric CVC-VTE.
- To highlight the emerging role of direct oral anticoagulants (DOACs) in this population.
Main Methods:
- Comprehensive literature search of PubMed from 1990 to present.
- Focus on studies addressing CVC-related VTE in pediatric patients.
- Inclusion of data on anticoagulant therapies, including dalteparin and DOACs.
Main Results:
- Recent publications include phase 3 trial results for pediatric DOACs.
- Dalteparin is currently the only FDA-approved anticoagulant for pediatric VTE.
- Current DOAC trials may not adequately represent children at the highest risk for CVC-VTE.
Conclusions:
- Direct oral anticoagulants (DOACs) offer a promising, orally administered, and potentially unmonitored alternative for pediatric anticoagulation.
- Further research is needed to establish optimal dosing and efficacy of DOACs in high-risk pediatric populations.
- Addressing the gap in evidence for CVC-related VTE in children is crucial for improving patient outcomes.
Introduction:
Acutely ill and medically complex pediatric patients typically rely on central venous catheters (CVCs) for vascular access. CVCs can have serious complications, including venous thromboembolism (VTE). In children, CVCs are the most common risk factor for VTE.
Area Covered:
Studies focused on the prevention and treatment of CVC-related VTE in children have been lacking until recently. Currently, there is one U.S. Food and Drug Administration (FDA) approved anticoagulant, dalteparin, and phase 3 trial results for two direct oral anticoagulants (DOACs) in pediatrics have recently been published. This review focuses on the epidemiology, risk factors, prevention, and treatment for CVC-related VTE in children. Data are included from relevant articles in PubMed, 1990 to present.
Expert Opinion:
With a paucity of FDA-approved anticoagulants for VTE treatment or prophylaxis in children, dosing and monitoring recommendations are often based largely on adult studies. DOACs are a promising group of anticoagulants to be used for children since they are given orally and do not require monitoring. Currently, children at the highest risk for CVC-related VTE are not well represented in the published pediatric DOAC trials.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care

